|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regulation of uncoupling protein-2 mRNA in L6 myotubules:Ⅱ:Thyroid hormone amplifies stimulation of uncoupling protein-2 gene by thiazolidines and other peroxisome proliferatoractivated receptor ligands in L6 myotubules:evidence for a priming effect显示文摘 | Lopez SI Marie V Camirand A | 2002 | Endocrine2002，19，2： | 1 |
| 2 | High-density lipoprotein regulates angiogenesis by long non-coding RNA HDRACA显示文摘Normal high-density lipoprotein(nHDL)can induce angiogenesis in healthy individuals.However,HDL from patients with coronary artery disease undergoes various modifications,becomes dysfunctional(dHDL),and loses its ability to promote angiogenesis.Here,we identified a long non-coding RNA,HDRACA,that is involved in the regulation of angiogenesis by HDL.In this study,we showed that nHDL downregulates the expression of HDRACA in endothelial cells by activating WW domain-containing E3 ubiquitin protein ligase 2,which catalyzes the ubiquitination and subsequent degradation of its transcription factor,Kruppel-like factor 5,via sphingosine 1-phosphate(S1P)receptor 1.In contrast,dHDL with lower levels of S1P than nHDL were much less effective in decreasing the expression of HDRACA.HDRACA was able to bind to Ras-interacting protein 1(RAIN)to hinder the interaction between RAIN and vigilin,which led to an increase in the binding between the vigilin protein and proliferating cell nuclear antigen(PCNA)mRNA,resulting in a decrease in the expression of PCNA and inhibition of angiogenesis.The expression of human HDRACA in a hindlimb ischemia mouse model inhibited the recovery of angiogenesis.Taken together,these findings suggest that HDRACA is involved in the HDL regulation of angiogenesis,which nHDL inhibits the expression of HDRACA to induce angiogenesis,and that dHDL is much less effective in inhibiting HDRACA expression,which provides an explanation for the decreased ability of dHDL to stimulate angiogenesis. | Zhi-Wei Mo Yue-Ming Peng Yi-Xin Zhang Yan Li Bi-Ang Kang Ya-Ting Chen Le Li Mary GSorci-Thomas Yi-Jun Lin Yang Cao Si Chen Ze-Long Liu Jian-Jun Gao Zhan-Peng Huang Jia-Guo Zhou Mian Wang Guang-Qi Chang Meng-Jie Deng Yu-Jia Liu Zhen-Sheng Ma Zuo-Jun Hu Yu-Gang Dong Zhi-Jun Ou Jing-Song Ou | 2023 | Signal Transduction and Targeted Therapy2023，8，9： | 1 |
| 3 | The Impact of the 2003 Regulatory Reform in the Canadian Property/Casualty Insurance Industry on Insurers' Surplus Levels 显示文摘 | Peter Carayannopoulos Mary Kelly and Si Li | 2003 | Journal of Insurance Issues2003，，： | 1 |
| 4 | Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma显示文摘 | Seil S Mary EM Si C | 2014 | Respir Res2014，15，： | 1 |
| 5 | Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans显示文摘 | Andrew Fire Si Q X Mary K M | 1998 | Nature1998，391，6669： | 1 |
| 6 | Glucocorticoids-potent modulators of astrocytic calcium signaling显示文摘 | Marie SI William T Could W | 1999 | Glia1999，28，1： | 1 |
| 7 | Updated spirometric reference values for adult Chinese in Hong Kong and implications on climcal utilization显示文摘 | MARY SI FANNY WK ARTHUR CL | 2006 | CHEST2006，129，2： | 1 |
| 8 | Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib:Multicenter French clinical experience in real-life after matching显示文摘BACKGROUND Starting a second-line systemic treatment for hepatocellular carcinoma(HCC)is a common situation.The only therapeutic options in France are two broadspectrum tyrosine kinase inhibitors(TKIs),regorafenib(REG)and cabozantinib(CBZ),but no comparative real-life studies are available.AIM To evaluate the progression-free survival(PFS)of patients treated with REG or CBZ,we investigated the disease control rate(DCR),overall survival(OS),and safety of both drugs.To identify the variables associated with disease progression over time.METHODS A retrospective multicenter study was performed on the clinical data of patients attending one of three referral centers(Avignon,Marseille,and Nice)between January 2017 and March 2021 using propensity score matching.PFS and OS were assessed using the Kaplan-Meier method.Multivariate analysis(MA)of progression risk factors over time was performed in matched-pair groups.RESULTS Fifty-eight patients 68(62-74)years old with HCC,Barcelona clinic liver cancer(BCLC)B/C(86%),Child-Pugh(CP)-A/B(24%)received REG for 3.4(1.4-10.5)mo as second-line therapy.Twentyeight patients 68(60-73)years,BCLC B/C(75%),CP-A/B(25%)received CBZ for 3.7(1.8-4.9)mo after first-line treatment with sorafenib[3(2-4)(CBZ)vs 4(2.9-11.8)mo(REG),P=0.0226].Twenty percent of patients received third-line therapy.After matching,PFS and DCR were not significantly different after a median follow-up of 6.2(2.7-11.7)mo(REG)vs 5.2(4-7.2)mo(CBZ),P=0.6925.There was no difference in grade 3/4 toxicities,dose reductions,or interruptions.The OS of CP-A patients was 8.3(5.2-24.8)vs 4.9(1.6-11.7)mo(CP-B),P=0.0468.The MA of risk factors for progression over time identified C-reactive protein(CRP)>10 mg/L,neutrophil-to-lymphocyte ratio(NLR)>3,and aspartate aminotransferase(AST)>45 IU as predictive factors.CONCLUSION This multicenter indirect comparative study found no significant difference in PFS between REG and CBZ as second-line therapy for advanced HCC.Elevated levels of inflammatory markers(CRP and NLR)and AST were associated with non-control of TKIs over time.A 2-mo online progression risk calculation is proposed. | Xavier Adhoute Marie De Matharel Laurent Mineur Guillaume Pénaranda Dann Ouizeman Clemence Toullec Albert Tran Paul Castellani Armelle Rollet Valérie Oules HervéPerrier Si Nafa Si Ahmed Marc Bourliere Rodolphe Anty | 2022 | World Journal of Gastrointestinal Oncology2022，14，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员